UNIGE document Scientific Article
previous document  unige:74558  next document
add to browser collection

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report

Agnandji, Selidji T.
CollaborationWith : Yerly Ferrillo, Sabine / Auderset, Floriane / Combescure, Christophe / Desmeules, Jules Alexandre / Finckh, Axel / Goncalves Cabecinhas, Ana Rita / Kaya, Gurkan / Lemaitre, Barbara / Matthey, Alain / Kaiser, Laurent / Siegrist, Claire-Anne
Published in New England Journal of Medicine. 2016, vol. 374, no. 17, p. 1647-1660
Abstract The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.
PMID: 25830326
Full text
Article (Published version) (787 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://www.nejm.org/doi/abs/10.1056/NEJMoa1502924
Research groups Groupe Laurent Kaiser (virologie clinique) (668)
Centre de vaccinologie et d'immunologie néonatale (177)
Mécanisme de l'inflammation articulaire (44)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Epidémiologie clinique (115)
(ISO format)
AGNANDJI, Selidji T. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report. In: New England Journal of Medicine, 2016, vol. 374, n° 17, p. 1647-1660. https://archive-ouverte.unige.ch/unige:74558

343 hits



Deposited on : 2015-08-10

Export document
Format :
Citation style :